We compared Turkish patients with cardiac syndrome X (CSX) and controls with respect to serum pro- and anti-inflammatory cytokine levels, as well as the single-nucleotide polymorphisms located in the promoter regions of their related genes. This study included 111 consecutive patients angiographically diagnosed with CSX and 111 healthy controls with similar demographic characteristics. Serum interleukin (IL) 6, tumor necrosis factor α (TNF-α), and IL-10 levels were measured, and the genotypes of the patients and controls were determined using standard methods. Serum IL-6 and IL-10 levels were significantly higher in the CSX group than in the control group (P < .01, respectively). Serum TNF-α level was lower in the CSX group than in the control group (P < .001). On the other hand, participants with CSX and healthy controls were not significantly different with respect to the genotype distributions of IL-6, TNF-α, and IL-10 genes. As a result of our study, both pro-inflammatory and anti-inflammatory cytokines may play a role in the pathogenesis of CSX. In contrast, the studied gene polymorphisms did not influence CSX pathogenesis.
CannonROIIIEpsteinSE. “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988;61(15):1338–1343.
2.
KempHGElliottWCGorlinR. The anginal syndrome with normal coronary arteriography. Trans Assoc Am Physicians. 1967;80:59–70.
3.
SinghMSinghSAroraRKhoslaS. Cardiac syndrome X: current concepts. Int J Cardiol. 2010;142(2):113–119.
4.
CreaFCamiciPGBairey MerzCN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101–1111.
5.
SamadFRufW. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415–3422.
6.
Recio-MayoralARimoldiOECamiciPGKaskiJC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging. 2013;6(6):660–667.
7.
SakrSAAbbasTMAmerMZ. Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction. Int Heart J. 2009;50(4):407–419.
8.
AsifaGZLiaquatAMurtazaIKazmiSAJavedQ. Tumor necrosis factor-alpha gene promoter region polymorphism and the risk of coronary heart disease. Sci World J. 2013;2013:203492.
9.
AukrustPSandbergWJOtterdalK. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med. 2011;43(2):90–103.
10.
ZhangHParkYWuJ. Role of TNF-α in vascular dysfunction. Clin Sci (Lond). 2009;116(3):219–230.
11.
AbeywardenaMYLeifertWRWarnesKEVargheseJNHeadRJ. Cardiovascular biology of interleukin-6. Curr Pharm Des. 2009;15(15):1809–1821.
12.
SeinoYIkedaUIkedaM. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6(1):87–91.
13.
Pinderski OslundLJHedrickCCOlveraT. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999;19(12):2847–2853.
14.
CavusogluEMarmurJDHojjatiMR. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med. 2011;124(8):724–730.
15.
WelshPMurrayHMFordI. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol. 2011;31(10):2338–2344.
16.
AntonicelliROlivieriFBonafeM. The interleukin-6 −174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol. 2005;103(3):266–271.
17.
FoxKGarciaMAArdissinoD. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. Eur Heart J. 2006;27(11):1341–1381.
18.
LiJJLiYSZhangYGaoZLiZQianHY. Inflammation: a possible pathogenic link to cardiac syndrome X. Med Hypotheses. 2006;66(1):87–91.
19.
SchuettHLuchtefeldMGrothusenCGroteKSchiefferB. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215–222.
20.
LiJJZhuCGNanJL. Elevated circulating inflammatory markers in female patients with cardiac syndrome X. Cytokine. 2007;40(3):172–176.
21.
GoodwinBLPendletonLCLevyMMSolomonsonLPEichlerDC. Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol. 2007;293(2): H1115–H1121.
22.
MirhafezSRZarifianAEbrahimiM. Relationship between serum cytokine and growth factor concentrations and coronary artery disease. Clin Biochem. 2015;48(9):575–580.
23.
LiuJJiaYLiX. Serum interleukin-10 levels and adverse events in patients with acute coronary syndrome: a systematic review and meta-analysis. Chin Med J (Engl). 2014;127(1):150–156.
24.
FiehnCPaleologEMFeldmannM. Selective enhancement of endothelial cell VCAM-1 expression by interleukin-10 in the presence of activated leucocytes. Immunology. 1997;91(4):565–571.
25.
LanzaGASestitoACammarotaG. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol. 2004;94(1):40–44.
26.
Cosin-SalesJPizziCBrownSKaskiJC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol. 2003;41(9):1468–1474.
27.
TeragawaHFukudaYMatsudaK. Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart. 2004;90(7):750–754.
28.
CartyCLHeagertyPHeckbertSR. Interaction between fibrinogen and Il-6 genetic variants and associations with cardiovascular disease risk in the cardiovascular health study. Ann Hum Genet. 2010;74(1):1–10.
29.
ManginasATsiavouAChaidaroglouA. Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coron Artery Dis. 2008;19(8):575–582.
30.
AdamopoulosSKolokathisFGkouzioutaA. Cytokine gene polymorphisms are associated with markers of disease severity and prognosis in patients with idiopathic dilated cardiomyopathy. Cytokine. 2011;54(1):68–73.
31.
MishraASrivastavaAMittalTGargNMittalB. Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients. Cytokine. 2013;61(3):856–861.
32.
MannilaMNErikssonPEricssonCGHamstenASilveiraA. Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost. 2006;95(3):420–427.
33.
StrieterRMKunkelSLBoneRC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21(suppl 10):S447–S463.
34.
MarcusGMWhooleyMAGliddenDVPawlikowskaLZaroffJGOlginJE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the heart and soul study. Am Heart J. 2008;155(2):303–309.
35.
LiYYFengYQKadokamiT. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A. 2000;97(23):12746–12751.
36.
SkoogTvan’t HooftFMKallinB. A common functional polymorphism (C-->A substitution at position −863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet. 1999;8(8):1443–1449.
37.
BernardVPilloisXDubusI. The −308 G/a tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med. 2003;41(4):511–516.
38.
JeanmonodPvon KanelRMalyFEFischerJE. Elevated plasma C-reactive protein in chronically distressed subjects who carry the a allele of the TNF-alpha −308 G/a polymorphism. Psychosom Med. 2004;66(4):501–506.
39.
BoehmJHaunerKGrammerJ. Tumor necrosis factor-alpha −863 C/a promoter polymorphism affects the inflammatory response after cardiac surgery. Eur J Cardiothorac Surg. 2011;40(1):e50–e54.
40.
GargPRSaraswathyKNKallaAKSinhaEGhoshPK. Pro-inflammatory cytokine gene polymorphisms and threat for coronary heart disease in a North Indian Agrawal population. Gene. 2013;514(1):69–74.
41.
BittarMNCareyJABarnardJB. Tumor necrosis factor alpha influences the inflammatory response after coronary surgery. Ann Thorac Surg. 2006;81(1):132–137.
42.
YoonSZJangIJChoiYJ. Association between tumor necrosis factor alpha 308G/A polymorphism and increased proinflammatory cytokine release after cardiac surgery with cardiopulmonary bypass in the Korean population. J Cardiothorac Vasc Anesth. 2009;23(5):646–650.
43.
GalinanesMJamesMCoddVBaxiAHadjinikolaouL. TNF-alpha gene promoter polymorphism at nucleotide −308 and the inflammatory response and oxidative stress induced by cardiac surgery: role of heart failure and medical treatment. Eur J Cardiothorac Surg. 2008;34(2):332–337.
44.
HenningsenKMOlesenMSPedersenM. Single nucleotide polymorphisms in inflammatory genes and the risk of early onset of lone atrial fibrillation. Inflamm Res. 2010;59(11):965–969.
45.
HenningsenKMOlesenMSRavnLS. Inflammatory single nucleotide polymorphisms and the risk of atrial fibrillation: a case control study. Inflamm Res. 2011;60(3):209–211.
46.
StuberFUdalovaIABookM. −308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm. 1995;46(1):42–50.
47.
HeiskanenMKahonenMHurmeM. Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the cardiovascular risk in young finns study. Atherosclerosis. 2010;208(1):190–196.
48.
KutikhinAGYuzhalinAEBrusinaEBPonasenkoAVGolovkinASBarbarashOL. Genetic predisposition to calcific aortic stenosis and mitral annular calcification. Mol Biol Rep. 2014;41(9):5645–5663.
49.
MarousiSEllulJAntonacopoulouAGogosCPapathanasopoulosPKarakantzaM. Functional polymorphisms of interleukin 4 and interleukin 10 may predict evolution and functional outcome of an ischaemic stroke. Eur J Neurol. 2011;18(4):637–643.
50.
TuttolomondoADi RaimondoDForteGI. Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to toast subtype. Cytokine. 2012;58(3):398–405.
51.
SultanaSKollaVKJeediguntaY. Tumour necrosis factor alpha and interleukin 10 gene polymorphisms and the risk of ischemic stroke in South Indian Population. J Genet. 2011;90(2):361–364.
52.
KilpinenSHuhtalaHHurmeM. The combination of the interleukin-1alpha (IL-1alpha-889) genotype and the interleukin-10 (IL-10 Ata) haplotype is associated with increased interleukin-10 (IL-10) plasma levels in healthy individuals. Eur Cytokine Netw. 2002;13(1):66–71.
